# Prosperity Bancshares Inc: financial statements, quarterly

PB · NYSE · CIK 1068851 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pb.md) · [Financials](/companies/pb/financials.md) · [Filings](/companies/pb/filings.md) · [Insiders](/companies/pb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [141](/filings/0000950170-23-058907.md) | [139 d](/filings/0000950170-24-022171.md) | [144](/filings/0000950170-24-055845.md) | [154](/filings/0000950170-24-092984.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [30.4](/filings/0000950170-24-123332.md) | [25.9 d](/filings/0001193125-26-077437.md) | [30.8](/filings/0000950170-25-066804.md) | [31.3](/filings/0000950170-25-104932.md) | [35.2](/filings/0001193125-25-270362.md) | [36.0 d](/filings/0001193125-26-077437.md) | [36.2](/filings/0001193125-26-215187.md) | [37.0](/filings/0001193125-26-338254.md) | [38.5](/filings/0001193125-25-270362.md) | [39.1 d](/filings/0001193125-26-077437.md) | [34.1](/filings/0001193125-26-215187.md) | [46.5](/filings/0001193125-26-338254.md) |
| Net income | $m | [112](/filings/0000950170-24-123332.md) | [95.5 d](/filings/0001193125-26-077437.md) | [110](/filings/0000950170-25-066804.md) | [112](/filings/0000950170-25-104932.md) | [127](/filings/0001193125-25-270362.md) | [130 d](/filings/0001193125-26-077437.md) | [130](/filings/0001193125-26-215187.md) | [135](/filings/0001193125-26-338254.md) | [138](/filings/0001193125-25-270362.md) | [140 d](/filings/0001193125-26-077437.md) | [116](/filings/0001193125-26-215187.md) | [169](/filings/0001193125-26-338254.md) |
| Diluted EPS | $ per share | [1.20](/filings/0000950170-24-123332.md) | not reported | [1.18](/filings/0000950170-25-066804.md) | [1.17](/filings/0000950170-25-104932.md) | [1.34](/filings/0001193125-25-270362.md) | not reported | [1.37](/filings/0001193125-26-215187.md) | [1.42](/filings/0001193125-26-338254.md) | [1.45](/filings/0001193125-25-270362.md) | not reported | [1.16](/filings/0001193125-26-215187.md) | [1.67](/filings/0001193125-26-338254.md) |
| Basic EPS | $ per share | [1.20](/filings/0000950170-24-123332.md) | not reported | [1.18](/filings/0000950170-25-066804.md) | [1.17](/filings/0000950170-25-104932.md) | [1.34](/filings/0001193125-25-270362.md) | not reported | [1.37](/filings/0001193125-26-215187.md) | [1.42](/filings/0001193125-26-338254.md) | [1.45](/filings/0001193125-25-270362.md) | not reported | [1.16](/filings/0001193125-26-215187.md) | [1.67](/filings/0001193125-26-338254.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [39.3](/filings/0000950170-23-058907.md) | [38.5](/filings/0000950170-25-029222.md) | [38.8](/filings/0000950170-24-055845.md) | [39.8](/filings/0000950170-24-092984.md) | [40.1](/filings/0000950170-24-123332.md) | [39.6](/filings/0001193125-26-077437.md) | [38.8](/filings/0000950170-25-066804.md) | [38.4](/filings/0000950170-25-104932.md) | [38.3](/filings/0001193125-25-270362.md) | [38.5](/filings/0001193125-26-338254.md) | [43.6](/filings/0001193125-26-215187.md) | [43.9](/filings/0001193125-26-338254.md) |
| Total liabilities | $bn | [32.3](/filings/0000950170-23-058907.md) | [31.5](/filings/0000950170-25-029222.md) | [31.7](/filings/0000950170-24-055845.md) | [32.5](/filings/0000950170-24-092984.md) | [32.8](/filings/0000950170-24-123332.md) | [32.1](/filings/0001193125-26-077437.md) | [31.2](/filings/0000950170-25-066804.md) | [30.8](/filings/0000950170-25-104932.md) | [30.7](/filings/0001193125-25-270362.md) | [30.8](/filings/0001193125-26-338254.md) | [35.4](/filings/0001193125-26-215187.md) | [35.6](/filings/0001193125-26-338254.md) |
| Shareholders' equity | $bn | [7.0](/filings/0000950170-24-123332.md) | [7.1](/filings/0001193125-26-077437.md) | [7.1](/filings/0000950170-25-104932.md) | [7.3](/filings/0001193125-25-270362.md) | [7.4](/filings/0001193125-25-270362.md) | [7.4](/filings/0001193125-26-338254.md) | [7.5](/filings/0001193125-26-338254.md) | [7.6](/filings/0001193125-26-338254.md) | [7.7](/filings/0001193125-25-270362.md) | [7.6](/filings/0001193125-26-338254.md) | [8.2](/filings/0001193125-26-338254.md) | [8.3](/filings/0001193125-26-338254.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [244 d](/filings/0000950170-24-123332.md) | [27.9 d](/filings/0001193125-26-077437.md) | [187](/filings/0000950170-25-066804.md) | [216 d](/filings/0000950170-25-104932.md) | [275 d](/filings/0001193125-25-270362.md) | [(206) d](/filings/0001193125-26-077437.md) | [178](/filings/0001193125-26-215187.md) | [98.2 d](/filings/0001193125-26-338254.md) | [195 d](/filings/0001193125-25-270362.md) | [78.3 d](/filings/0001193125-26-077437.md) | [185](/filings/0001193125-26-215187.md) | [162 d](/filings/0001193125-26-338254.md) |
| Capital expenditure | $m | [11.2 d](/filings/0000950170-24-123332.md) | [4.6 d](/filings/0001193125-26-077437.md) | [7.2](/filings/0000950170-25-066804.md) | [4.7 d](/filings/0000950170-25-104932.md) | [4.4 d](/filings/0001193125-25-270362.md) | [4.8 d](/filings/0001193125-26-077437.md) | [7.1](/filings/0001193125-26-215187.md) | [6.4 d](/filings/0001193125-26-338254.md) | [9.2 d](/filings/0001193125-25-270362.md) | [9.9 d](/filings/0001193125-26-077437.md) | [7.0](/filings/0001193125-26-215187.md) | [4.6 d](/filings/0001193125-26-338254.md) |
| Dividends paid | $m | [51.5 d](/filings/0000950170-24-123332.md) | [52.5 d](/filings/0001193125-26-077437.md) | [52.4](/filings/0000950170-25-066804.md) | [53.4 d](/filings/0000950170-25-104932.md) | [53.3 d](/filings/0001193125-25-270362.md) | [55.3 d](/filings/0001193125-26-077437.md) | [55.3](/filings/0001193125-26-215187.md) | [55.3 d](/filings/0001193125-26-338254.md) | [55.1 d](/filings/0001193125-25-270362.md) | [55.8 d](/filings/0001193125-26-077437.md) | [60.6](/filings/0001193125-26-215187.md) | [60.4 d](/filings/0001193125-26-338254.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-123332.md) | [0.0 d](/filings/0001193125-26-077437.md) | [35.3](/filings/0000950170-25-066804.md) | [39.5 d](/filings/0000950170-25-104932.md) | [0.0 d](/filings/0001193125-25-270362.md) | [0.0 d](/filings/0001193125-26-077437.md) | not reported | not reported | not reported | [137 d](/filings/0001193125-26-077437.md) | [57.1](/filings/0001193125-26-215187.md) | [13.7 d](/filings/0001193125-26-338254.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [91.2](/filings/0000950170-23-058907.md) | [91.2](/filings/0000950170-24-055845.md) | [92.9](/filings/0000950170-24-092984.md) | [93.7](/filings/0000950170-24-123332.md) | [93.7](/filings/0000950170-25-066804.md) | [95.8](/filings/0000950170-25-104932.md) | [95.3](/filings/0001193125-25-270362.md) | [95.3](/filings/0001193125-26-215187.md) | [95.3](/filings/0001193125-26-338254.md) | [95.1](/filings/0001193125-25-270362.md) | [99.8](/filings/0001193125-26-215187.md) | [101](/filings/0001193125-26-338254.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 120,176,771 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338254.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.